ROBIN SHERRINGTON
SEC CIK 1619962 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | EVP, Strategy, Innovation | 9,632 | — | $3.49M | 10 | 2022-03-04 | 2024-03-07 |
Most active insiders at XENE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | MORTIMER IAN | Pres, CEO, INTERIM CFO, Dir | — | $21.30M |
| 2 | KENNEY CHRISTOPHER JOHN | Chief Medical Off | — | $670.3K |
| 3 | GANNON STEVEN | Dir | — | $640.6K |
| 4 | DiFabio Andrea | CLO | — | $230.8K |
| 5 | PATOU GARY | Dir | — | $70.3K |
| 6 | Cannon Gillian | Dir | — | $63.2K |
| 7 | GAROFALO ELIZABETH A. | Dir | — | — |
| 8 | Gover Justin D. | Dir | — | — |
| 9 | Svoronos Dawn | Dir | — | — |
| 10 | Machado Patrick | Dir | — | — |
ROBIN SHERRINGTON made no open-market trades at XENE in the last 12 months.
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-08 | 2024-03-07 | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $9.85 | +8,641 | 9,632 | +872% | +$85.1K |
| DM | 2024-03-08 | 2024-03-07 | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | S - Sale+OE | $46.28 | -7,137 | 14.5K | -33% | -$330.3K |
| DM | 2024-03-08 | 2024-03-07 | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | F - Tax | $45.96 | -1,504 | 15.5K | -9% | -$69.1K |
| 2024-01-02 | 2023-12-29 | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | J - Other | $0.00 | -8,398 | 8,398 | -50% | $0 | |
| DM | 2022-09-02 | 2022-08-31+ | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $4.25 | +72.5K | 34.7K | New | +$307.9K |
| DM | 2022-09-02 | 2022-08-31+ | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | F - Tax | $38.62 | -7,693 | 60.7K | -11% | -$297.1K |
| DM | 2022-09-02 | 2022-08-31+ | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | S - Sale+OE | $38.31 | -65.2K | 25.6K | -72% | -$2.50M |
| DM | 2022-03-08 | 2022-03-04 | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | M - OptEx | $3.67 | +7,406 | 38.9K | +23% | +$27.2K |
| D | 2022-03-08 | 2022-03-04 | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | F - Tax | $31.42 | -696 | 32.8K | -2% | -$21.9K |
| DM | 2022-03-08 | 2022-03-04 | XENE | Xenon Pharmaceuticals Inc. | ROBIN SHERRINGTON | EVP, Strategy, Innovation | S - Sale+OE | $30.50 | -21.7K | 32.2K | -40% | -$662.2K |
Purchase Sale Sale after option exercise All abbreviations